Omeros Share Price - OMER

-0.01 (-0.06%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
USA Small Cap Basic
Monthly Subscription
for only
North American Extreme
Monthly Subscription
for only
USA Big Cap Pro
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Price Change % Stock Price Last Trade
-0.01 -0.06% 15.45 13:45:02
Open Price Low Price High Price Close Price Previous Close
15.50 15.36 15.7078 15.46
Bid Price Ask Price Spread News
15.45 15.47 0.02 - -
Trades Stocks Traded VWAP Financial Volume Average Volume 52 Week Range
2,538 209,602 US$ 15.48 US$ 3,244,846 667,177 9.25 - 25.49
Last Trade Type Quantity Price Currency
13:44:40 5 US$ 15.45 USD

Omeros Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 962.97M 62.33M 59.75M US$ 73.81M US$ - -2.40 -6.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- US$ - - -146.33k 4.20%

more financials information »

Omeros News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMER Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week14.9815.707814.5015.13575,7180.473.14%
1 Month14.0516.6214.0215.42516,3951.409.96%
3 Months17.8919.3913.8616.82596,997-2.44-13.64%
6 Months14.6623.8513.8618.15668,9870.795.39%
1 Year15.9325.499.2515.28902,638-0.48-3.01%
3 Years18.5227.008.5015.65695,978-3.07-16.58%
5 Years10.9527.08827.2015.75741,1354.5041.1%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210623 19:00:13